By Lucy Parkinson, VP of Investor Research, LSN

In addition to maintaining the LSN Investor Platform, LSN also provides access to the LSN Business Development platform, which tracks tens of thousands of early stage companies and new life science technologies all over the world.  This platform includes a licensing deals dataset that provides crucial information on valuations, milestones, upfront payments, and everything else you’d need to build valuation comparators for your assets.  By taking a look at all the 2019 data as a whole, we can reveal what’s really happening in pharma dealmaking.

We have recently expanded our deals records and due to the change in the way we compile this data, year-over-year comparisons are difficult.  But here are the key facts that emerge from the 2019 deals data.

Partnering Starts Early

While 2019 saw a good deal of horse-trading of assets that were already on the market (including many deals for regional rights in Asia), we continue to see a lot of early stage companies locking in deals at the Research, Preclinical or Phase I stages.  As you can see by the chart, about a third of 2019’s deals that pertained to a specific therapeutic asset happened prior to Phase II.

Oncology, Oncology, Oncology

In 2019, dealmakers continued their hunt for new targets and treatments for cancer. Many assets were licensed that did not specify an indication or did not pertain to a specific disease area (this is often true of new drug platforms or delivery technologies), but among those that did, oncology continued to have an outsized presence.  However, we saw an uptick in interest in infectious diseases and in gastroenterology.  In the infectious space, there were several deals for HIV treatments, and in gastroenterology, there was interest in Crohn’s disease, NASH and IBS.  Neurology also remained an active field for deals, with in-licensing efforts related to multiple sclerosis and epilepsy, among other disease areas.

There are hundreds of potential licensees out there, and they have deep pockets

Every time we take a look into licensing deals data, we find deals being made with a huge variety of organizations all over the world.  From traditional big pharmas and global conglomerates to rising biotechs and even philanthropic foundations that are making co-development deals with startups – there’s no shortage of dealmakers out there, and if you’re looking for a partner for your early stage asset you should spread your net wide.  We captured a total of over 170 organisations that made an in-licensing deal in 2019.  About half of all deals included a stated upfront payment, and over half also stated a milestone payment – sometimes in the billions of dollars.

While not all deals are made public, within our data set the most highly active dealmakers in 2019 were AstraZeneca and Gilead.  We’ll keep our eyes peeled during 2020 for in-licensing activity from these firms and hundreds more.

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Last week I wrote about why every entrepreneur needs to build a fundraising campaign that utilizes comprehensive marketing collateral and includes a strategy for getting in front of the right partners to help move your company forward. However, equally as important is an innovative technology, a compelling story and sufficient data to prove how effective your product is.

Early stage innovators need to get their products developed through prototyping for a target market, then get out of the building and go after that market (investors, end users, channel partners) with their product info and validating data. The key is emphasizing and differentiating their technology, proving why they are different and telling the story of what that difference will mean.  You have to start telling the story early.  Preclinical and IND stages are where you want to be talking about how your technology will impact the existing landscape, and you must deliver a prototype with data to prove it.

The lean company model, in which LSN believes, is to get your technology going and take it to the potential partners in your space (LSN can identify them) that would be interested, and build momentum and relationship value through early stage interaction. Attending RESI, which is held every few months, allows you to regularly meet your potential partners face to face and develop deeper relationships as the products iterate, instead of meeting once or twice a year. This is why RESI is so pivotal: because all the different but relevant players are at every RESI. LSN provides the tactical aspect of how to engage partners in discussion and where to find them.

Ultimately, a company cannot succeed without using all of these pieces to put together a complete picture: a product that continues to meet important milestones, a compelling story backed up by a complete marketing collateral package, and on-going relationships with investors and strategic partners to move it forward. However, the product and the validation data is the foundation on which everything stands, and it needs to be solid to avoid crashing to the ground.

By Claire Jeong, Director of Research, Asia BD, LSN

After finishing off our most successful RESI to date and recovering from JPM week, we are ramping up our preparations for the upcoming RESI Europe Conference, which will be at the Hyatt Regency Paris Étoile on Monday, March 23^rd, 2020. We expanded into Europe for the first time last year, and it is super exciting to be able to go to Paris for our second European conference. We look forward to fostering valuable connections and relationships, as well as working with a lot of new companies and investors/strategic partners based in Europe.

We are anticipating over 200 investors to join us at the event from across the globe. Please take advantage of our Super Early Bird Rate by using our €100 discount code SUPEREBEU on our registration here (expires on Sunday, February 2^nd). Hope to see you in Paris!

CONFIRMED RESI EUROPE INVESTORS AND STRATEGIC PARTNERS

As of  January 30th, 2020

And More…